Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | CTSV | O60911 | 3/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.56 |
| ▸ | TUBB | P07437 | 1/20 | 0.56 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.56 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.56 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.56 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.56 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.56 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.56 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.56 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.56 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11556879 | 0.79 | HPGD (0.58) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL1354245 | 0.78 | PARP1 (0.63) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL28460210 | 0.78 | HPGD (0.56) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL7964360 | 0.78 | HPGD (0.56) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL4890491 | 0.78 | HPGD (0.56) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL11659575 | 0.78 | HPGD (0.56) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL30234473 | 0.77 | LMNA (0.53) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL15775297 | 0.77 | PARP1 (0.67) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL27944081 | 0.76 | HPGD (0.50) | HPGDLMNAKDM4ECTSVCTSL | |
| SCHEMBL4670793 | 0.74 | DAO (0.56) | HPGDLMNAKDM4EHSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897833-B1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-02-06 | — | — | US | disclosed |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-13 | — | — | US | disclosed |
| CN-118221563-A | Synthesis method of 2-aryl indole | 南京工业大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-113453760-B | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-04 | — | — | US | disclosed |
| CN-109665984-B | Synthetic method of 2-substituted indole compound | 南京工业大学 | 2022-03-04 | — | — | CN | disclosed |
| EP-3897833-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453760-A | APOL1 inhibitors and methods of use thereof | 弗特克斯药品有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmacéuticals Incorporated | 2020-12-03 | — | — | US | disclosed |
| WO-2020131807-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| US-20080039625-A1 | Screening Methods | LAUTENS MARK | 2008-02-14 | — | — | US | disclosed |
| EP-1817283-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | Lautens, Mark (CA) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006047888-A1 | 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF | LAUTENS MARK (CA) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | HPGD 2403/4885LMNA 912/4885KDM4E 4311/4885 |
| US-12060346-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, SAAL1 | HPGD 2403/4885LMNA 912/4885KDM4E 4311/4885 |
| US-20080039625-A1 | Screening Methods | CBR3, ZKSCAN2, CRBN | HPGD 4276/4885LMNA 344/4885KDM4E 3829/4885 |
| US-20250042878-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | HPGD 2403/4885LMNA 912/4885KDM4E 4311/4885 |
| US-11618746-B2 | Inhibitors of APOL1 and methods of using same | APOL1, APOB, NPC1L1 | HPGD 1574/4885LMNA 983/4885KDM4E 4249/4885 |
| US-20200377479-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, SAAL1, LOXL1 | HPGD 2080/4885LMNA 1084/4885KDM4E 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.